UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2021

MICROBOT MEDICAL INC.
(Exact name of registrant as specified in its charter)

Delaware	**000-19871**	**94-3078125**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

25 Recreation Park Drive, Unit 108
Hingham, Massachusetts 02043
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (781) 875-3605

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.01 par value	MBOT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure.

On January 14, 2021, Microbot Medical Inc. (the "Company") issued a press release announcing that the continued progression of its LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world's first fully disposable surgical robotic system. The animal feasibility studies to date, support the Company's assertion that LIBERTY will potentially allow physicians to safely and easily conduct catheter-based peripheral and neurovascular procedures remotely, avoiding radiation exposure, physical strain and the risk of cross contamination.

The Company is also furnishing presentation materials as Exhibit 99.2 to this Current Report on Form 8-K, which may also be accessed via the 'Investors' section, under 'Presentations + Resources' of the Registrant's website at www.microbotmedical.com. The Company is not undertaking to update this presentation.

The press release furnished as Exhibit 99.1 and the presentation furnished as Exhibit 99.2 to this Current Report on Form 8-K are incorporated herein by reference. The information in this report (including Exhibits 99.1 and 99.2) is being furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information herein (including Exhibits 99.1 and 99.2).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release
99.2	Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MICROBOT MEDICAL INC.

By: */s/ Harel Gadot*
Name: Harel Gadot
Title: Chief Executive Officer, President and Chairman

Date: January 14, 2021

Exhibit 99.1

Microbot Medical Announces Positive Results of Additional Animal Feasibility Study with LIBERTY™ Robotic System

Results Validate Findings of Initial Study; End Points Achieved with No Intraoperative Adverse Events

Management Presenting at Needham Growth Conference Today at 2:00pm ET

HINGHAM, Mass., January 14, 2021 – The continued progression of Microbot Medical Inc.'s (Nasdaq: MBOT) LIBERTY™ Robotic System was further demonstrated as the Company announced the successful completion of an additional feasibility animal study using the world's first fully disposable surgical robotic system. The study end points included navigating to a clot, crossing the clot, deploying a stent retriever, and manually retrieving an arterial clot in a live pig. All the end points were met with no intraoperative adverse events. The animal feasibility studies to date, support the Company's assertion that LIBERTY will potentially allow physicians to safely and easily conduct catheter-based peripheral and neurovascular procedures remotely, avoiding radiation exposure, physical strain and the risk of cross contamination.

"As we continue to evaluate LIBERTY in the hands of leading clinicians, the system is performing to our expectations and achieving the desired clinical and usability outcomes," commented Harel Gadot, Chief Executive Officer, President, and Chairman. "Additional studies are planned throughout the coming year to allow us to achieve our regulatory goals."

The procedure was performed by Dr. Gal Yaniv, a recently added member of the Company's Scientific Advisory Board (SAB), who also serves as Director of Endovascular Neurosurgery at Sheba Tel HaShomer City of Health and Chief Medical Officer of Aidoc Medical, a full body imaging AI software firm. Dr. Yaniv conducted the procedure and the results demonstrated robust navigation capabilities and intuitive usability.

Mr. Gadot will be presenting an overview of the Company later today at 2:00pm ET. The live and archived replays of the presentation may be accessed via the 'Investors' section, under 'Presentation + Resources' of the Company's website at www.microbotmedical.com.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).

Microbot Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available at http://www.microbotmedical.com.

Safe Harbor

Statements pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects" and "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization of potential products, including LIBERTY™ and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Investor Contact:

Michael Polyviou
EVC Group
mpolyviou@evcgroup.com
732-933-2754

Exhibit 99.2

microbot medical

SAFE HARBOR STATEMENT

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, relating to future events or the future financial performance and operations of Microbot Medical, INC. Forward-looking statements, which involve assumptions and describe Microbot's intent, belief or current expectations about its business opportunities, prospects, performance and results, are generally identifiable by use of the words "may," "could," "should," "will," "would," "expect," "anticipate," "plan," "potential," "estimate," "believe," "intend," "project," "forecast," the negative of such words and other variations on such words or similar terminology. All statements other than statements of historical fact could be deemed forward-looking statements, including, but not limited to: risks inherent in the development and/or commercialization of potential products, including LIBERTY and the self-cleaning shunt; the outcome of our studies to evaluate LIBERTY and the SCS and other existing and future technologies; uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals; uncertainty resulting from the COVID-19 pandemic; need and ability to obtain future capital; maintenance of intellectual property rights; our ability to find and develop applications for our technologies for other neurosurgical conditions besides hydrocephalus; our clinical development and other research and development plans and expectations; the safety and efficacy of our product candidates; the anticipated regulatory pathways for our product candidates; our ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of our product candidates and commercialize any approved products on our expected timeframes or at all; the content and timing of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory agencies; our ability to leverage the experience of our management team; and any statements or assumptions underlying any of the items mentioned. These forward-looking statements are not guarantees of future performance and by their nature involve known and unknown risks and uncertainties that may cause actual opportunities, prospects, performance and results to vary from those presented in this document, and those variances may be material. In evaluating such statements, prospective investors should carefully consider the various risks and uncertainties identified in Microbot's public filings with the Securities and Exchange Commission (the "SEC"), such as market risk, liquidity risk, competitive risk, regulatory risk and other commonly recognized forms of risk relating to Microbot and its securities. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this document might not occur. Microbot is not obligated to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of Microbot's securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

MEDICAL ROBOTICS MARKET IS RAPIDLY GROWING

Minimally Invasive Surgery (MIS) is the fastest growing healthcare segment
>$50B

Expected
>20% CAGR
through 2025

Applies to
Most Surgical Specialties

Becoming
Smaller, Automated, and More Precise

SURGICAL ROBOTICS GROWTH OPPORTUNITY

U.S. Market for Surgical Robotics

Microbot Medical is in the Right Market, at the Right Time with the Right Products!

HEALTHCARE LANDSCAPE
POSITIONED FOR POST COVID-19

- Telehealth has been a core focus of Microbot's product development roadmap
- LIBERTY and SCS are designed to be remote controlled and monitored

Cardiovascular Today, April 2020
COVID-19: Robotics may help to reduce exposure to virus patients during interventional procedures

ResearchGate, March 2020
Robotics For COVID-19: How Can Robots Help Health Care in the Fight Against Coronavirus?

WIRED, March 2020
The Covid-19 Pandemic Is a Crisis That Robots Were Built For

MEDICAL ROBOTICS REMAINS IN THE SPOTLIGHT

Medtronic Announces Acquisition of Digital Surgery to Accelerate Robot Assisted Surgery Strategy.
Globe Newswire, February 2020

Intuitive Surgical Acquires Orpheus Medical for Undisclosed Amount.
Globe Newswire, February 2020

Stryker Acquires Mobius Imaging and Cardan Robotics for $370 million upfront and up to $130 million of contingent payments correlated with development and commercial milestones.
Globe Newswire, September 2019

Corindus Vascular Robotics Announces Definitive Agreement to be Acquired by Siemens Healthineer for $1.1 billion
Business Wire, August, 2019

Johnson & Johnson Acquires Auris Health, Inc for $3.4 billion in cash. Additional contingent payments of up to $2.35 billion, in the aggregate, may be payable upon reaching certain predetermined milestones.
Globe Newswire, April 2019

Medtronic Acquires Mazor Robotics for $1.64 Billion.
PR Newswire, September 2018

EVOLUTION OF SURGERY



MULTIPLE OPPORTUNITIES – ENDOLUMINAL SURGERY



2020 SHOWED SIGNIFICANT PROGRESS

Strengthened Balance Sheet

Strengthened IP Portfolio:
40 Global Patents Issued/Allowed
24 Pending Patent Applications

First Pre-submission Meeting with the FDA Regarding the SCS

Animal Feasibility Studies End Points Met

liberty microbot medical

Unveiled First Ever Fully Disposable Robotic System

Bolstered Leadership Team:
Dr. Morag, CMO
Dr. Noa Ofer, IP/Regulatory

Recruited Thought Leaders to Enhance Core Capabilities:

- **Scientific Advisory Board:**
  Dr. Neeman, Dr. Yaniv, Dr. Wakhloo, Dr. Solomon, Dr. Rabkin
- **Board of Directors:**
  Aileen Stockburger, Tal Wenderow


liberty
microbot medical

FULLY DISPOSABLE ROBOTIC SYSTEM

Eliminate Need for Capital Equipment

Operated Remotely

"One & Done" Capabilities

LAST 12 MONTHS AT-A-GLANCE



FIRST ANIMAL FEASIBILITY STUDY

The study end point was met

- Peripheral and Neuro Procedures Successfully Achieved
- No Intraoperative Adverse Effects
- Exceed internal expectations
- Confirmed Usability of the System with Leading KOL's

*The LIBERTY Robotic System is under its R&D phase, was not tested clinically and is not cleared for market within or outside the US

SECOND ANIMAL FEASIBILITY STUDY

The study end point was met

- Navigated to a clot
- Crossed the clot
- Deployed a stent retriever
- Retrieved an arterial clot in a live pig (manually)

CROSSING THE CLOT

INSERTION OF STENT RETRIEVER

*All of the end points were met with no intraoperative adverse events.

CONTINUED MOMENTUM IN 2021

- Conclude animal feasibility studies on LIBERTY Robotic System
- LIBERTY Robotic System design freeze
- Initiate Pivotal Animal Study
- Conclude EFS pre-submission with FDA (Self-Cleaning Shunt)
- FDA pre-submission request for LIBERTY Robotic System
- Continue to recruit medical pioneers and thought leaders
- Expand IP portfolio
- Explore M&A opportunities to enhance capabilities in vascular market segment

LIBERTY:
CLINICAL AND REGULATORY UPCOMING MILESTONES



microbot medical

SELF-CLEANING SHUNT (SCS): VENTRICULOPERITONEAL SHUNT MARKET OPPORTUNITY

- Hydrocephalus and Normal Pressure Hydrocephalus (NPH), are medical conditions in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain.
- Over 1,000,000 people in the United States currently live with hydrocephalus[1]



- The problem is often misdiagnosed as Dementia, Alzheimer's, or Parkinson's[2]
- NPH can cause dementia, difficulty in walking and urinary incontinence[2]

1. NIH, National Institute of Neurological Disorders and Stroke. http://www.ninds.nih.gov/disorders/hydrocephalus/detail_hydrocephalus.htm
2. National Hydrocephalus Foundation. http://nhfonline.org/facts-about-hydrocephalus.htm

SCS:
CLINICAL AND REGULATORY UPCOMING MILESTONES



ROBUST IP PLATFORM

PROVEN FOUNDERS

Prof. Moshe Shoham
Member of the Scientific Advisory Board

Prof. Moshe Shoham is a worldwide acclaimed authority in the field of robotics, conducting research in the robotic field for over the past 25 years, with a special focus on kinematics and dynamics of robots, sensor integration, multi-finger hands and medical applications.

- Founder of Mazor Robotics Ltd. acquired by Medtronic for $1.64B
- International Member, US National Academy of Engineering
- Head of the robotics lab at Technion's - Israel Institute of Technology - Faculty of Mechanical Engineering. Formerly the director of the robotic laboratory of the Department of Mechanical Engineering, Columbia University, NY.

Harel Gadot
CEO, President & Chairman

Mr. Harel Gadot was formerly a Worldwide Group Marketing Director at Ethicon Inc., a multi-billion dollar division of Johnson & Johnson company (NYSE: JNJ). Mr. Gadot was with J&J for a decade between 2000- 2010.

- Company Group Chairman for MEDX Ventures Group.
- Previously held leadership positions for Ethicon Inc. in Europe, Middle East and Africa.
- Served on the board of directors and led the business development for ConTIPI Ltd., an early stage medical device company, which was acquired by Kimberly Clark Corp (NYSE:KMB) in 2012.

Yossi Bornstein
Director

Mr. Yossi Bornstein is the President of Shizim Group, one of the leading MedTech eco-systems in Israel. He is a serial entrepreneur who played key roles in the healthcare industry over the past 35 years and is recognized for his activity both in Israel and internationally.

- He is a founder of multiple successful HealthCare companies and innovation centers, among them ShizimXL and ShizimVS.
- Previously he held the position of CEO at Bristol-Myers Squibb (BMS) in Israel.

PROVEN LEADERSHIP TEAM

Simon Sharon
Chief Technology Officer

Mr. Simon Sharon brings 23 years of R&D and general management in the medical devices space. Prior to Microbot Medical Mr. Sharon managed the R&D at Icecure Medical; an early stage, public medical device company. Mr. Sharon was the General Manager of Anorad Israel, a subsidiary of Rockwell Automation which manufactures sub-micron precision motion systems.

- Holds a B.Sc. from the Technion Institute of Technology and an M.Sc in Mechanical engineering from MIT where he specialized in motion control and Robotics.

Dr. Eyal Morag
Chief Medical Officer

Dr. Eyal Morag will lead the development and execution of the clinical strategy of the Company's technology platforms, including its current development of the Self-Cleaning Shunt (SCS) and LIBERTY products as well as its future pipeline.

- Member of the Company's Scientific Advisory Board since November 2017.
- Serves as Chairman of Radiology at Assuta Ashdod Medical Center, Ashdod, Israel.
- Recently served as the Regional Radiology Director at Mercy Health Partners Hospitals in Toledo, Ohio.
- Member of University Radiology Group (one of the largest private Radiology groups in the U.S.) where he headed the International Investment efforts for the Ventures division.

David Ben Naim
Chief Financial Officer

Mr. David Ben Naim is a CPA licensed in the State of Israel. Prior to joining Microbot Medical, Mr. Ben Naim operated DBN Financial.

- Previously served as CFO of Insuline Medical Ltd, a public company listed on the Tel-Aviv Stock Exchange (TASE:INSL).
- Prior to that Mr. Ben Naim served as CFO of Crow Technologies 1977 Ltd, a public company listed on the OTCQB (CRWTF), from 2008 – 2011.

SUMMARY

- Addressing multi-billion, high growth, underserved markets
- Developing micro-invasive medical robotic technology platforms to enhance clinician ability to treat patients with unmet medical needs
- Multi-generational product pipeline portfolio with robust launch cadence
- Significant IP creates barrier to entry
- Proven leadership team and continued involvement of founders, including Prof. Moshe Shoham, founder of Mazor Robotics
- Strong cash position to achieve meaningful milestones